Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 8
2007 15
2008 9
2009 8
2010 49
2011 102
2012 115
2013 77
2014 89
2015 71
2016 53
2017 43
2018 56
2019 32
2020 32
2021 33
2022 26
2023 16
2024 12
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

768 results

Results by year

Filters applied: . Clear all
Page 1
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Kantoff PW, et al. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. N Engl J Med. 2010. PMID: 20818862 Free article. Clinical Trial.
This reduction represented a 4.1-month improvement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group). The 36-month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group. …
This reduction represented a 4.1-month improvement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months i …
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE, Antonarakis ES. Handy CE, et al. Future Oncol. 2018 Apr;14(10):907-917. doi: 10.2217/fon-2017-0531. Epub 2017 Dec 20. Future Oncol. 2018. PMID: 29260582 Free PMC article. Review.
Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. ...This review will discuss the pivotal trials leading to approv …
Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic ac …
Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.
Graff JN, Chamberlain ED. Graff JN, et al. Core Evid. 2014 Dec 18;10:1-10. doi: 10.2147/CE.S54712. eCollection 2015. Core Evid. 2014. PMID: 25565923 Free PMC article. Review.
Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy shown to improve survival in prostate cancer. ...Finally, the only published economic analysis …
Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipul …
Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.
Yi R, Chen B, Duan P, Zheng C, Shen H, Liu Q, Yuan C, Ou W, Zhou Z. Yi R, et al. J Immunol Res. 2016;2016:4543861. doi: 10.1155/2016/4543861. Epub 2016 Dec 12. J Immunol Res. 2016. PMID: 28058266 Free PMC article. Review.
Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade 3 (p > 0.05). However, treatment with sipuleucel-T did not improve time-to-progression and …
Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increase …
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.
Sutherland SIM, Ju X, Horvath LG, Clark GJ. Sutherland SIM, et al. Front Immunol. 2021 Mar 29;12:641307. doi: 10.3389/fimmu.2021.641307. eCollection 2021. Front Immunol. 2021. PMID: 33854509 Free PMC article. Review.
Many tumors including prostate cancer are resistant to such treatment. However, Sipuleucel-T, a dendritic cell (DC) based immunotherapy, improved overall survival (OS) in prostate cancer. Despite this initial success, further DC vaccines have failed to progress and …
Many tumors including prostate cancer are resistant to such treatment. However, Sipuleucel-T, a dendritic cell (DC) based immu …
Pharmaco-economic aspects of sipuleucel-T.
Simoens S. Simoens S. Hum Vaccin Immunother. 2012 Apr;8(4):506-8. doi: 10.4161/hv.18334. Epub 2012 Feb 16. Hum Vaccin Immunother. 2012. PMID: 22336882 Free article. Review.
This Commentary aims to highlight pharmaco-economic aspects relating to the clinical evidence, cost-effectiveness and reimbursement of sipuleucel-T. Today, there is still uncertainty surrounding the clinical benefit of sipuleucel-T and existing evidenc …
This Commentary aims to highlight pharmaco-economic aspects relating to the clinical evidence, cost-effectiveness and reimbursement of si …
Sipuleucel-T.
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Higano CS, et al. Nat Rev Drug Discov. 2010 Jul;9(7):513-4. doi: 10.1038/nrd3220. Nat Rev Drug Discov. 2010. PMID: 20592741 No abstract available.
Sipuleucel-T (APC8015) for prostate cancer.
So-Rosillo R, Small EJ. So-Rosillo R, et al. Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. doi: 10.1586/14737140.6.9.1163. Expert Rev Anticancer Ther. 2006. PMID: 17020451 Review.
In men with hormone-refractory prostate cancer, clinical trials have demonstrated both biological activity and clinical response to sipuleucel-T. Data from two Phase III trials in men with asymptomatic, metastatic hormone-refractory prostate cancer demonstrated an i …
In men with hormone-refractory prostate cancer, clinical trials have demonstrated both biological activity and clinical response to sipul …
Sipuleucel-T (Provenge) for castration-resistant prostate cancer.
Di Lorenzo G, Ferro M, Buonerba C. Di Lorenzo G, et al. BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. BJU Int. 2012. PMID: 22177289 Review.
We aimed to provide a comprehensive review of available safety and efficacy data about Sipuleucel-T. METHODS: A systematic analysis of the literature was conducted using the terms 'Sipuleucel-T' and 'Provenge'. ...Such analysis has recently concluded t …
We aimed to provide a comprehensive review of available safety and efficacy data about Sipuleucel-T. METHODS: A systematic ana …
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Madan RA, et al. J Natl Cancer Inst. 2020 Jun 1;112(6):562-573. doi: 10.1093/jnci/djaa021. J Natl Cancer Inst. 2020. PMID: 32145020 Free PMC article. Review.
In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median = 4.1 months) vs placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (22.1 ng/mL) exhibited a 13 …
In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) …
768 results